Cortisol-Resistence Testing allows to Monitor and Control Steroid-Therapy

Approximately 20% of the patients treated by glucocorticoids develop resistance to the therapy.

These patients are unnecessarily exposed to the high risk of severe side effects due to increasing dosage of glucocorticoids during therapy. The diagnosis of a pre-existing or therapy induced steroid resistance can be made using the ActiQuant Oligo-ELISA kit and this can significantly reduce steroid-dependent secondary diseases.

The new Glucocorticoid-Receptor Activity-Test GR ActiQuant Oligo-ELISA is an effective tool for the quantitative determination of active and/or inactive form of Glucocorticoid receptor (GR) in extracts of peripheral blood monocytes and other type of cells.

The assay allows to monitor and control steroid therapy in e.g. Asthma, COPD, Rheumatoid Arthritis, and Autoimmune Diseases

Key Features of the new GR ActiQuant Oligo-ELISA:

• Simple 4 hours Test Procedure
• No use of radioactivity
• Works with whole blood samples
• Quantitative results
• Quantitative Measurement of either:
  -The ratio of active and inactive GR
  -Active GR alone
  -Total GR
   

Whitepaper-Download (317 KB)